Risa Konishi Selected Research

nuclear matrix protein 2

1/2024	Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.
1/2022	Case of anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis preceded by linear cutaneous lupus erythematosus on the face.
1/2022	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
1/2021	Clinically amyopathic dermatomyositis associated with anti-nuclear matrix protein 2 antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Risa Konishi Research Topics

Disease

7	Myositis (Idiopathic Inflammatory Myopathies) 02/2024 - 01/2022
5	Dermatomyositis (Dermatopolymyositis) 01/2024 - 01/2022
2	Pneumonia (Pneumonitis) 02/2024 - 03/2023
2	Experimental Nervous System Autoimmune Disease 02/2024 - 03/2023
2	Muscular Diseases (Myopathy) 02/2024 - 03/2023
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2024 - 01/2022
2	Neoplasms (Cancer) 01/2024 - 01/2022
2	Erythema 10/2023 - 10/2022
2	Amyopathic dermatomyositis 10/2022 - 01/2021
1	Acute Lung Injury 04/2024
1	Virus Diseases (Viral Diseases) 04/2024
1	Inflammation (Inflammations) 04/2024
1	Panniculitis 10/2023
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2022
1	Dermatitis 12/2022
1	Diarrhea 01/2022
1	Cutaneous Lupus Erythematosus 01/2022
1	Exanthema (Rash) 01/2022
1	Pruritus (Itching) 01/2022
1	Calcinosis 01/2022
1	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 01/2019

Drug/Important Bio-Agent (IBA)

5	AutoantibodiesIBA 02/2024 - 01/2022
4	nuclear matrix protein 2IBA 01/2024 - 01/2021
3	Proteins (Proteins, Gene)FDA Link 02/2024 - 04/2022
3	EnzymesIBA 01/2024 - 10/2022
2	AntibodiesIBA 02/2024 - 03/2023
2	AntigensIBA 02/2024 - 03/2023
2	AutoantigensIBA 02/2024 - 03/2023
2	Coenzyme A (CoA)IBA 02/2024 - 03/2023
2	Complement System Proteins (Complement)IBA 02/2024 - 03/2023
2	Immunoglobulin G (IgG)IBA 02/2024 - 10/2023
2	Ligases (Synthetase)IBA 02/2024 - 03/2023
2	Myosins (Myosin)IBA 02/2024 - 03/2023
2	Oxidoreductases (Dehydrogenase)IBA 02/2024 - 03/2023
2	UbiquitinIBA 10/2023 - 10/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2024
1	Poly I-CIBA 04/2024
1	Transfer RNA (tRNA)IBA 02/2024
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 02/2024
1	CytokinesIBA 01/2024
1	ImmunosorbentsIBA 01/2024
1	Interleukin-8 (Interleukin 8)IBA 01/2024
1	ChemokinesIBA 01/2024
1	SteroidsIBA 10/2023
1	IFIH1 Interferon-Induced HelicaseIBA 10/2023
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 10/2023
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2023
1	Intravenous Immunoglobulins (IVIG)FDA Link 10/2023
1	Histidine-tRNA LigaseIBA 03/2023
1	Imiquimod (Aldara)FDA LinkGeneric 12/2022
1	apremilastIBA 01/2022
1	Phosphodiesterase 4 InhibitorsIBA 01/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Immunoglobulin E (IgE)IBA 01/2019

Therapy/Procedure

1	Intranasal Administration 04/2024